Biologic Options in Pediatric Asthma
The panel discusses the biologic drugs approved for use in children with asthma, including omalizumab, dupilumab, mepolizumab, and the recently approved benralizumab. They share their preferences among these options for improving lung function in pediatric patients.
EP: 1.External Factors and Seasonality of Asthma
EP: 2.Endotypes and Phenotypes in Asthma
EP: 3.Type 2 Inflammation and Biomarkers in Asthma
EP: 4.Moderate/Severe/Uncontrolled Asthma Classification
EP: 5.Thinking About Endotypes when Managing Asthma
EP: 6.Use of Oral Corticosteroids in Asthma
EP: 7.High Oral Corticosteroid Dose and Exposure in Asthma
EP: 8.Oral Corticosteroid Overuse and Uncontrolled Asthma
EP: 9.Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma
EP: 10.Biologics in Asthma
EP: 11.GINA Guidelines and Biologics for Treatment of Asthma
EP: 12.Use of Biologics for Asthma in Patients with Allergies
EP: 13.Treatment of Asthma in Pediatric Patients
EP: 14.Atopic March in Pediatric Patients
EP: 15.Use of Biologics in Pediatric Patients and Conversations with Parents
Now Viewing
EP: 16.Biologic Options in Pediatric Asthma
Related Videos
Related Content
